EGFR
Epidermal growth factor receptor
Design a conditional EGFR binder
EGFR is one of the most clinically validated targets in oncology, and also one of the clearest illustrations of why affinity alone is not enough. This challenge asks for three properties that current EGFR therapeutics achieve only partially: binding human EGFR, binding the orthologs used in preclinical studies, and binding selectively in acidic tissue.
Submissions closed Wednesday, October 7, 23:59 AoE. Selection begins shortly.
EGFR extracellular region with a cetuximab Fab mutant · PDB 6ARU
Target information
Design against human EGFR’s extracellular region. We recommend targeting a functional epitope such as domain III.
Human EGFR
Extracellular region- UniProt reference
- P00533-1 ↗
- Target residues · UniProt
- 25–645 / 621 aa
- Recommended epitope
- Domain III
- Structure reference
- 6ARU · Chain A ↗
Amino acid sequence
LEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSThe targets' purification tags and your design's C-terminal Twin-Strep capture tag are off limits: binding to a tag does not count.
Three objectives
This challenge consists of 3 main objectives, and each will be accounted for when selecting the best designs.
01
Binding affinity
Design a binder against human EGFR. We recommend targeting a functional epitope such as domain III, which is also targeted by the therapeutic antibodies cetuximab and panitumumab.
We’ll measure its binding affinity using the full extracellular region of the human receptor.
02
Mouse cross-reactivity
In the next objective, you should design a binder that recognises both human and mouse EGFR. On top of the validation from Objective 1, we will test binding against the mouse EGFR.
Binding both species would make it easier to study the same design in mouse models before moving to human studies, without developing a separate mouse-specific binder.
How designs are ranked
Every tested design is measured in the same four conditions: human EGFR at pH 6.5 and at pH 7.4, and mouse EGFR at pH 6.5, with the design immobilised and the target in solution. A design counts as binding in a condition when its sensorgram gives a fittable curve and a KD, or, where the curve cannot be fitted, when the association shift clears 300% over the negative control. Otherwise we call it no detectable binding.
- 1
pH-selective binding
A measurable KD against human EGFR at pH 6.5 and no detectable binding at pH 7.4. Designs that bind at both pH values rank after these, by the ratio of their KD at pH 7.4 to their KD at pH 6.5. Designs that rely on a conformational change or a designed pH mechanism are not penalised when we select designs for testing; the measurement decides.
- 2
Mouse cross-reactivity
Binds mouse EGFR as well as human at pH 6.5, ranked by how close the mouse-to-human KD ratio is to 1, among designs whose human KD is below 1 µM.
- 3
Affinity
Lowest KD against human EGFR at pH 6.5. Binding at a functional epitope counts in its favour: name the epitope you target and link your evidence, or we read it from a predicted complex. The recommended epitope is a hint, not a rule: a design that binds elsewhere is measured and ranked all the same.
The winner has to clear all three steps, with ties settled in this order, and each step also awards an honourable mention to the best design that did not win.
Which designs are tested is a separate step from who wins. Track 1 teams get their ranked designs tested; for Tracks 2 and 3, Claude selects from all submissions with a prompt we publish in full.
Timeline
Sep 28 – Oct 7, 2026
Submissions open
Design, review, and submit. Submissions close Wednesday, October 7 at 23:59 Anywhere on Earth (AoE).
- 2nowSee other challenges
Submissions closed
The window is closed. No further designs are accepted for this challenge.
- 3
Selection in progress
Anthropic and Adaptyv select designs for synthesis using a Claude-based workflow, published after the competition.
- 4
Wet-lab validation in progress
Submission requirements
- Length
- 10–250 amino acids
- Format
- Single chain protein, nanobody, scFv, or Fab
- Designs per participant
- Up to 40 for Track 1, up to 20 for Tracks 2 and 3
- Design
- De novo designs only